Ribose-5-phosphate isomerase deficiency

Ribose-5-phosphate isomerase deficiency
Other names	RPI deficiency

Ribose-5-phosphate isomerase deficiency (RPID) is a rare human disorder caused by mutations in ribose-5-phosphate isomerase, an enzyme of the pentose phosphate pathway. With only four known cases – all diagnosed between 1984 and 2019 – RPI deficiency is the second rarest disease, with Fields condition being the rarest, affecting two known individuals, Catherine and Kirstie Fields.

Mechanism

In the search for an explanation for this rarity, it has been found that the patient has a seldom-seen allelic combination. One allele is a nonfunctional null allele, while the other encodes for a partially active enzyme. Furthermore, the partially functional allele has expression deficits that depend on the cell type in which it is expressed. Therefore, some of the patient's cells have a considerable amount of RPI activity, whereas others do not.

The molecular cause of the pathology is not fully understood. One hypothesis is that ribose-5-phosphate may be insufficient for RNA synthesis. Another possibility is that the accumulation of D-ribitol and D-arabitol may be toxic. However, Klussman et al. evaluated the toxicity of polyols on a rat neurochip model and concluded that the accumulation of polyols has likely only a secondary effect on brain dysfunction, if any at all.

In rat prefrontal cortex, mitochondrial superoxide production was elevated with the addition of ribitol, but not with arabitol. Furthermore, the activity of three antioxidant enzymes was increased under the influence of ribitol, while arabitol showed no such effect. Neither polyol had any impact on the glutathione content in the rat prefrontal cortex. Additionally, neither polyol influenced the oxidation levels of proteins or lipids.

Paradoxically, downregulation of ribose-5-phosphate isomerase in Drosophila melanogaster leads to a fitter phenotype: enhanced tolerance to oxidative stress and extended lifespan. Artificial downregulation of RPI has been therefore suggested as a treatment against disease caused by polyglutamine neutroxicity (such as Huntington's disease) but also to counteract normal ageing.

Diagnosis

Symptoms include optic atrophy, nystagmus, cerebellar ataxia, seizures, spasticity, psychomotor retardation, leukoencephalopathy and global developmental delay.

RPI can be diagnosed by gene sequencing or increased polyol levels in blood or urine. Patients also present highly elevated polyols in the brain, which can be revealed by proton magnetic resonance spectroscopy.

Treatment

There is no current treatment or prognosis for ribose-5-phosphate isomerase deficiency.

History

The first patient was a male born in 1984 to healthy, unrelated parents. Early in life, the patient had psychomotor retardation and developed epilepsy at age 4. From age 7, a slow neurological regression occurred with prominent cerebellar ataxis, some spasticity, optic atrophy, and a mild sensorimotor neuropathy with no observed organomegaly dysfunction of internal organs. MRI scans at age 11 and 14 revealed extensive abnormalities of the cerebral white matter and elevated levels of D-ribitol and D-arabitol.

In 1999 van der Knaap and colleagues reviewed this case of the then 14-year-old boy and characterised the associated symptoms of RPI deficiency as the following: developmental delay, insidious psychomotor regression, epilepsy, leukoencephalopathy and abnormal polyol metabolism. Later, Naik and colleagues reported a second case, an 18-year-old man with seizures, psychomotor regression and diffuse white matter abnormality. A third case was reported in 2018 by Sklower Brooks and colleagues, a child with neonatal onset leukoencephalopathy and psychomotor delays. A fourth case was reported in 2019 by Kaur and colleagues with progressive leukoencephalopathy and elevated urine polyols arabitol and ribitol.